Ulrico Dorighi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ulrico Dorighi has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Elena Scarsi
Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DINOGMI), University of Genoa, 16126 Genoa, Italy
2 shared publications - Enrico Adriano
Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DINOGMI), University of Genoa, 16126 Genoa, Italy
2 shared publications - Marina Grandis
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal and Infantile Sciences (DINOGMI), University of Genoa, Largo P. Daneo 3, 16132 Genova, Italy
2 shared publications - Maurizio Balestrino
University of Genoa, Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Sciences (DINOGMI), Italy;IRCCS Ospedale Policlinico San Martino, Genova, Italy, Italy
2 shared publications
Latest Publications
- Open Access
- 27 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (23) , 7194
Low-Dose Creatine Supplementation May Be Effective in Early-Stage Statin Myopathy: A Preliminary Study
Background. Statins are the main cholesterol-lowering treatments, but often they are stopped because of statin myopathy. Expensive second-line treatments are then prescribed, causing a burden on the health system. Previous research showed that creatine supplementation may be a relatively inexpensive, safe, and effective way to mitigate statin toxicity to the muscle. Methods. We thus investigated the tolerability and effectiveness of creatine supplementation in consecutive patients with statin myopathy, as observed at our Cardiology or Neurology outpatient services for previous cardiac or cerebral ischemic disease. Results. We confirmed previous findings showing that creatine supplementation is safe and well tolerated even in this elderly population. Eleven of the thirteen enrolled patients completed the study, and only one patient interrupted the study because of a creatine-related issue (elevation of serum creatinine). Creatine supplementation significantly reduced the Shewmon and Craig’s “myopathy score”, while it did not reduce serum creatine kinase (CK), a marker of muscle structural damage. Notably, creatine supplementation was effective at a dose of 1 g. t.i.d., lower than usually prescribed in the international literature and within the recommendations of health agencies like the Italian Ministry of Health. Conclusion. Creatine supplementation may improve statin myopathy in its milder and/or earlier form when serum CK is not elevated. Since creatine is relatively inexpensive, its supplementation may be used instead of switching from statins to the very expensive second-line anti-cholesterol treatments.
- 27 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (23) , 7194
Open AccessLow-Dose Creatine Supplementation May Be Effective in Early-Stage Statin Myopathy: A Preliminary Study
Background. Statins are the main cholesterol-lowering treatments, but often they are stopped because of statin myopathy. Expensive second-line treatments are then prescribed, causing a burden on the health system. Previous research showed that creatine supplementation may be a relatively inexpensive, safe, and effective way to mitigate statin toxicity to the muscle. Methods. We thus investigated the tolerability and effectiveness of creatine supplementation in consecutive patients with statin myopathy, as observed at our Cardiology or Neurology outpatient services for previous cardiac or cerebral ischemic disease. Results. We confirmed previous findings showing that creatine supplementation is safe and well tolerated even in this elderly population. Eleven of the thirteen enrolled patients completed the study, and only one patient interrupted the study because of a creatine-related issue (elevation of serum creatinine). Creatine supplementation significantly reduced the Shewmon and Craig’s “myopathy score”, while it did not reduce serum creatine kinase (CK), a marker of muscle structural damage. Notably, creatine supplementation was effective at a dose of 1 g. t.i.d., lower than usually prescribed in the international literature and within the recommendations of health agencies like the Italian Ministry of Health. Conclusion. Creatine supplementation may improve statin myopathy in its milder and/or earlier form when serum CK is not elevated. Since creatine is relatively inexpensive, its supplementation may be used instead of switching from statins to the very expensive second-line anti-cholesterol treatments.
- Open Access
- 26 September 2024
- Published by MDPI AG in Preprints.org
Low-Dose Creatine Supplementation May Be Effective in Early-Stage Statin Myopathy: An Observational, Preliminary Study
Statins are the main cholesterol-lowering treatments, but often they are stopped because of statin myopathy. Expensive second-line treatments are then prescribed, causing a burden on the health system. Creatine supplementation may be a safe, effective and cheap alternative this shift. We investigated tolerability and possible effectiveness of creatine supplementation in statin myopathy. Our data confirmed previous findings showing that creatine supplementation is safe and well tolerated even in this elder population. In fact, 11 of the 13 enrolled patients completed the study, and only one patient interrupted the study because of a creatine-related issue (elevation of serum creatinine). Creatine supplementation significantly reduced the Shewmon and Craig’s “myopathy score”, while it did not reduce serum creatine kinase (CK), a marker of muscle structural damage. Notably, creatine supplementation was effective at the dose of 1g. t.i.d., lower that usually prescribed in international literature and within the recommendations of health agencies like the Italian Ministry of Health. Thus, creatine supplementation may improve statin myopathy in its milder and/or earlier form, when serum CK is not elevated. Moreover, creatine supplementation may prevent or delay switching from statins to the very expensive second-line anti-cholesterol treatments.
- 26 September 2024
- Published by MDPI AG in Preprints.org
Open AccessLow-Dose Creatine Supplementation May Be Effective in Early-Stage Statin Myopathy: An Observational, Preliminary Study
Statins are the main cholesterol-lowering treatments, but often they are stopped because of statin myopathy. Expensive second-line treatments are then prescribed, causing a burden on the health system. Creatine supplementation may be a safe, effective and cheap alternative this shift. We investigated tolerability and possible effectiveness of creatine supplementation in statin myopathy. Our data confirmed previous findings showing that creatine supplementation is safe and well tolerated even in this elder population. In fact, 11 of the 13 enrolled patients completed the study, and only one patient interrupted the study because of a creatine-related issue (elevation of serum creatinine). Creatine supplementation significantly reduced the Shewmon and Craig’s “myopathy score”, while it did not reduce serum creatine kinase (CK), a marker of muscle structural damage. Notably, creatine supplementation was effective at the dose of 1g. t.i.d., lower that usually prescribed in international literature and within the recommendations of health agencies like the Italian Ministry of Health. Thus, creatine supplementation may improve statin myopathy in its milder and/or earlier form, when serum CK is not elevated. Moreover, creatine supplementation may prevent or delay switching from statins to the very expensive second-line anti-cholesterol treatments.